Hariharan M J, Driver D A, Townsend K, Brumm D, Polo J M, Belli B A, Catton D J, Hsu D, Mittelstaedt D, McCormack J E, Karavodin L, Dubensky T W, Chang S M, Banks T A
Department of Viral Therapeutics, Center for Gene Therapy, Chiron Technologies, San Diego, California 92121-1204, USA.
J Virol. 1998 Feb;72(2):950-8. doi: 10.1128/JVI.72.2.950-958.1998.
Previously we reported the development of a plasmid DNA expression vector system derived from Sindbis virus (T. W. Dubensky, Jr., et al., J. Virol. 70:508-519, 1996). In vitro, such vectors exhibit high-level heterologous gene expression via self-amplifying cytoplasmic RNA replication. In the present study, we demonstrated the in vivo efficacy of the Sindbis virus-based pSIN vectors as DNA vaccines. A single intramuscular immunization of BALB/c mice with pSIN vectors expressing the glycoprotein B of herpes simplex virus type 1 induced a broad spectrum of immune responses, including virus-specific antibodies, cytotoxic T cells, and protection from lethal virus challenge in two different murine models. In addition, dosing studies demonstrated that the pSIN vectors were superior to a conventional plasmid DNA vector in the induction of all immune parameters tested. In general, 100- to 1,000-fold-lower doses of pSIN were needed to induce the same level of responsiveness as that achieved with the conventional plasmid DNA vector. In some instances, significant immune responses were induced with a single dose of pSIN as low as 10 ng/mouse. These results indicate the potential usefulness of alphavirus-based vectors for DNA immunization in general and more specifically as a herpes simplex virus vaccine.
先前我们报道了一种源自辛德毕斯病毒的质粒DNA表达载体系统的研发情况(小T.W. 杜本斯基等人,《病毒学杂志》70:508 - 519, 1996年)。在体外,此类载体通过自我扩增的细胞质RNA复制表现出高水平的异源基因表达。在本研究中,我们证明了基于辛德毕斯病毒的pSIN载体作为DNA疫苗的体内功效。用表达1型单纯疱疹病毒糖蛋白B的pSIN载体对BALB/c小鼠进行单次肌肉注射免疫,可诱导广泛的免疫反应,包括病毒特异性抗体、细胞毒性T细胞,并在两种不同的小鼠模型中提供对致死性病毒攻击的保护。此外,剂量研究表明,pSIN载体在诱导所有测试免疫参数方面优于传统质粒DNA载体。一般而言,诱导与传统质粒DNA载体相同水平的反应性,所需的pSIN剂量要低100至1000倍。在某些情况下,单剂量低至10 ng/小鼠的pSIN就能诱导显著的免疫反应。这些结果表明,一般来说基于甲病毒的载体在DNA免疫方面具有潜在用途,更具体地说,可作为单纯疱疹病毒疫苗。